This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kiguchi, K. Articles by DiGiovanni, J. Search for Related Content PubMed PubMed Citation Articles by Kiguchi, K. Articles by DiGiovanni, J.

Chemopreventive and Therapeutic Efficacy of Orally Active Tyrosine Kinase Inhibitors in a Transgenic Mouse Model of Gallbladder Carcinoma

Authors' Affiliations: ¹ Department of Carcinogenesis, The University of Texas, M.D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas and ² Department of Surgery, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

Requests for reprints: John DiGiovanni, Department of Carcinogenesis, The University of Texas, M. D. Anderson Cancer Center, Science Park-Research Division, 1808 Park Road 1C, P.O. Box 389, Smithville, TX 78957. Phone: 512-237-9414; Fax: 512-237-2444; E-mail: jdigiovanni{at}sprd1.mdacc.tmc.edu.

Biliary tract cancer (BTC) is the second most common primary hepatobiliary cancer after hepatocellular cancer. At the time of diagnosis, most BTC are at an advanced stage and are unresectable. There is presently no effective curative treatment of the advanced disease nor is there any effective clinical therapy that will prevent the development of BTC. All of these factors render gallbladder cancer nearly incurable with a poor survival rate. The aim of our study was to provide a better understanding of the mechanisms involved in the development of gallbladder carcinoma as the advancement of more effective treatment options would significantly improve prognosis. In the present study, we examined the effect of gefitinib, a selective epidermal growth factor receptor/tyrosine kinase inhibitor (EGFR/TKI), on the development of gallbladder carcinoma in BK5.erbB2 mice. In addition, we examined the effect of another quinazoline derivative, GW2974, which is able to block the activation of both the EGFR and erbB2, in this model. Animals were treated with either 400 ppm gefitinib or 200 ppm GW2974 as a supplement in the diet using either a chemopreventive or therapeutic protocol. The results show that both compounds were potent chemopreventive and therapeutic agents in this mouse model of human BTC. The results also suggest that activation of the EGFR plays an important role in development of BTC in this model and that targeting both the EGFR and erbB2 may be an effective strategy for treatment of this disease.

This article has been cited by other articles:

				M. Mimeault and S. K. Batra Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies Ann. Onc., October 1, 2007; 18(10): 1605 - 1619. [Abstract] [Full Text] [PDF]

				K. Kiguchi, L. Ruffino, T. Kawamoto, E. Franco, S.-i. Kurakata, K. Fujiwara, M. Hanai, M. Rumi, and J. DiGiovanni Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice Mol. Cancer Ther., June 1, 2007; 6(6): 1709 - 1717. [Abstract] [Full Text] [PDF]

				Q. Wu, K. Kiguchi, T. Kawamoto, T. Ajiki, J. Traag, S. Carbajal, L. Ruffino, H. Thames, I. Wistuba, M. Thomas, et al. Therapeutic Effect of Rapamycin on Gallbladder Cancer in a Transgenic Mouse Model Cancer Res., April 15, 2007; 67(8): 3794 - 3800. [Abstract] [Full Text] [PDF]